DEERFIELD, Ill.--(BUSINESS WIRE)--April 20, 2006--Dade Behring Inc.(NASDAQ:DADE - News), the world’s largest company solely dedicated to clinical diagnostics, announced today that they have granted rights to American Diagnostica, a manufacturer and supplier of clinical diagnostics and research products, for the in vitro diagnostic use of factor VII-activating protease (FSAP) for the development of diagnostic tests that are intended to be used in the detection of the early stages of cardiovascular disease and to study the role of FSAP in coagulation disorders. This agreement also provides American Diagnostica with the rights to sell FSAP antibodies.
